Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HH-003 in Chronic Hepatitis Delta Virus Infection
NCT05861674Phase 2Completed
- Sponsor
- Huahui Health
- Start
- Jun 2023
- Primary completion
- Jul 2024
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of Libevitug in Hepatitis delta virus infection (HDV), sponsored by Huahui Health. Started Jun 2023; status: completed.
02
Drugs
Libevitug
03
Conditions
Hepatitis delta virus infection (HDV)
Beyond the preview
Go deeper on NCT05861674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05861674.